STUDresearch · Peptide
Vesugen
Also known as
KED peptide · KED · Lys-Glu-Asp · Lysyl-glutamyl-aspartic acid · H-Lys-Glu-Asp-OH · vascular bioregulator · Vezugen (Russian transliteration) · Vesogen (common misspelling) · T-38 (research designation) · Khavinson vascular tripeptide · vascular cytogen (Khavinson class)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Mixed
Oral / sublingual / SubQ
Longevity & bioregulators
Mixed — vascular-targeted framing, but oral, sublingual and SubQ use is systemic rather than a local vessel treatment.
What people say
Vesugen is synthetic KED, a three-amino-acid peptide discussed as a vascular cytogen. It is not Ventfort, the animal-tissue vessel peptide complex, and modern human dose-ranging and PK packages are absent.
Doses people talk about
These are retail, clinic-chart and one forum-history amounts, not a dose progression. No controlled human dose-ranging study validates the injectable charts.
How it may feel
No dependable acute feel is established. Reports range from no clear signal to vague circulation or recovery benefit, usually inside multi-peptide histories; one long follow-up explicitly said the added agents blurred causality.
Oral capsule chart~10 mg per capsule
Retail notes describe 1–2 capsules 1–2× daily for about 20–30 days; mass and formulation vary by brand.
Sublingual product chart~5–6 drops (~0.25–0.35 mL)
Older guides describe this amount 3–4× daily; an alternate chart describes ~10–12 drops twice daily.
Actual multi-agent forum course1 mg/day SubQ for 20 days
The same history also used Cartalax after FGF-18 and later added more agents; the author said causality was blurred.
Half-life & effect duration
- Half-life in the body
- Community expectationHours-scale; no agreed number
- Felt duration people report
- Multi-product accountsVague benefit or joint / vascular observations, without an isolated Vesugen timeline
Cycles people discuss
Discussion centers on 10–30-day injection blocks or roughly one-month oral or drop courses, followed by months off. Longer ramps and multi-organ rotations are later community practices, not validated exposure schedules.
Timing
Oral charts place capsules around meals, drop charts use repeated pre-food contact, and injection charts usually describe once-daily use. These habits do not establish a human KED half-life or a felt-duration clock.
Stacks
Vesugen is discussed with Ventfort as a vessel pair and in rotating pineal, thymus, vessel and cartilage calendars. The actual forum outcome history also included Cartalax and FGF-18, so it cannot isolate Vesugen.
Watch for
Long-term data gap: No solid multi-year safety database for continuous or repeatedly cycled gray-market synthetic KED.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No product-specific human elimination half-life was established for synthetic KED.
The literature review describes KED sequence and proposed cellular effects, while the profile's hours-scale language is community expectation rather than measured human PK.
The accessed review is from the originator research lineage and is not a Vesugen ADME study; oral, sublingual and SubQ products cannot be assumed equivalent.
- Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease (opens in a new tab)PubMed abstract and metadata: KED identity, oral-use claim and proposed gene/protein effects; no product-specific human pharmacokinetic result in the accessed abstract. Actual abstract and references read.Narrative review from the originating research network, focused on neurogenesis rather than vascular use; not an ADME or dose-ranging study.
Felt duration people report
No isolated onset or felt-duration window survives the mixed and heavily stacked reports.
A Reddit discussion included vague multi-bioregulator benefit and a non-specific Vesugen/Ventfort follow-up; a separate arthritis history used Vesugen with Cartalax after FGF-18 and later more agents.
Self-selected reports, unclear product identity, multiple co-interventions and no objective Vesugen-specific endpoint.
- Peptide Bioregulators — Experiences? (opens in a new tab)Read the full discussion, including the pineal/thymus/vessel-stack report at about one month and jaygatz76's later Vesugen/Ventfort follow-up saying several formulations seemed beneficial without Vesugen-specific detail.Multiple authors and products; vague subjective endpoints, no isolated Vesugen exposure, no verified formulations and no dependable same-author quantitative follow-up.
- Peptides for arthritis? — Vesugen/Cartalax follow-up history (opens in a new tab)Page 4, post #61 quoting Cataceous's prior update and subsequent same-history update: 1 mg/day SubQ Vesugen for 20 days with 2 mg/day Cartalax after FGF-18; later FOXO4-DRI, IGF-1 LR3 and another combined course; author said causality may be blurred and later nothing much had changed yet.Quoted history with numerous sequential and simultaneous interventions, an arthritis endpoint and no isolated Vesugen comparison.
What people say
- eNOS / NO narratives: Community and vendor summaries claim improved NO-dependent vasorelaxation; primary literature is thin and often secondary citations. forum
- Feel anecdotes: Warmer extremities, easier walking recovery, milder ‘pump’ or training continuity — highly confounded by stacks, BP meds, and expectation. anecdote
- Stack halo: Multi-bioregulator calendars (pineal + thymus + vessel) make single-agent credit unreliable. forum
- Pace expectation: Gradual vessel-support narrative over a course/post-course window — not acute nitro-like vasodilator kick or BP crash. forum
- Endothelin-1 (cells): KED reported to normalize elevated endothelin-1 expression in endothelial models of atherosclerosis/restenosis. lab
- Gap junctions (cells): Connexin markers and intercellular communication described as improved after KED in endothelial work. lab
- SIRT1 (cells): Abstracts report higher sirtuin-1 as a geroprotective endothelial signal. lab
- Ki-67 / proliferation (cells): Upregulation of proliferation-associated Ki-67 / MKI67 promoter talk in aged vascular-cell cultures; sometimes framed as restoring renewal capacity. lab
- Lower-limb arterial insufficiency (human, small): Older Russian series in elderly chronic lower-limb arterial disease re-cited for clinical + ultrasonic blood-flow improvement after vessel bioregulators including Vezugen. trial
- Vasculogenic ED (human, n≈41): Adv Gerontol–linked Vezugen series reported improved penile arterial flow by clinical and Doppler-style measures after ~1 capsule daily for ~1 month; community often quotes ~53–61% flow-velocity figures and ~+7 sexual-function score points with residual signal at ~4 months — single-source, unreplicated Western RCT. trial
- Neuro / AD models (animals): Daily IP KED (~400 μg/kg in 5xFAD mice, ~2 months) associated with dendritic-spine preservation and neuroprotective gene-expression shifts; oral KED observational memory/attention notes in elderly CNS dysfunction are originating-group claims. animal
- Ischemia models (animals): Reduced infarct size / survival talk in preclinical ischemia contexts — not human stroke therapy. animal
- Atherosclerosis candidacy: Preclinical vasoprotective candidate only; not proven primary CV prevention. animal
- CV symptom add-on talk: Russian clinical narratives sometimes pair vessel peptides with standard care for angina frequency, arrhythmia comfort, sleep, or longer remission between hypertensive crises — adjunct framing, not monotherapy proof. trial
Doses people talk about
- Oral capsules (most common commercial cytogen form): Often marketed as ~10 mg peptide per capsule; charts commonly say 1–2 capsules 1–2× daily with food (or 5–10 min before meals) for ~20–30 days / ~1 month. forum
- Oral mass ambiguity: Some product lines list different mg-per-capsule or multi-component fills; ‘1–2 caps’ is not automatically equal across brands. forum
- Sublingual / lingual drops: Older product guides: ~5–6 drops (~0.25–0.35 mL) under tongue, hold ~10–15 min before eating, ~3–4× daily for ~1 month; alternate charts say ~10–12 drops 2× daily. forum
- Injectable clinic-style short course: Widely repeated as ~1–2 mg/day subcutaneous for ~10 consecutive days, repeated ~2–3× per year. forum
- Injectable mid-range (gray-market charts): ~0.5–1 mg SC once daily for ~10–30 days is a common ‘research protocol’ band. forum
- Titration ramps (vendor/educational sites): Start ~500 mcg daily week 1 → ~1,000 mcg week 2 → ~1,500 mcg week 3 → target ~1,500–2,000 mcg daily weeks 4–8+ (sometimes extended toward ~12–16 weeks). These long ramps diverge from classic 10–30 day bioregulator blocks and lack dose-response trials. forum
- Split higher inject talk: Minority blogs mention ~2 mg/day split 1 mg BID, or even ~4–5 mg/day for ‘severe vascular’ claims — poorly sourced relative to short-course literature and often criticized as escalation without PK. forum
- Reddit / forum band: Injectable users commonly land on ~0.5–2 mg/day or a flat ~2 mg QD × 10 days; oral Ventfort often stacked alongside. forum
- Oral vs inject non-interchangeability: Oral microgram-to-low-mg historical courses and modern multi-mg SC vial culture are different PK starting lines; copying oral caps math onto a 20 mg vial (or vice versa) is a common error. forum
- Uncertainty flags: Cytogen capsule vs research lyophilizate purity, mg vs mcg chart typos, and ‘Vesugen’ vs multi-peptide blends are frequent gray-market problems. forum
- Age-frequency talk (institute-style charts, not RCTs): Rough community tables: ~25–35 y → 1–2 courses/year preventive; ~40–45 → ~2/year; ~50+ → ~3/year. forum
- Oral ED-series style: Small Russian vasculogenic-ED writeups describe ~1 capsule daily for ~1 month — a conservative oral block often cited as the human reference. trial
- Framing: Discussion and vendor/clinic chart ranges only — not medical advice, not FDA/EMA-validated protocols; no controlled human dose-ranging study anchors any injectable figure. forum
- No approved label: Compound is research-only in most Western jurisdictions; numbers are community/supplier conventions. trial
How it may feel
- Days 1–3: Little acute change expected; no strong vasodilator ‘kick’; oral users may note nothing or mild GI. forum
- Days 4–10: Common first window for mild extremity warmth, recovery ease, or still flat — very individual. forum
- Days 10–20 / end of short inject course: Checkpoint for circulation comfort or training continuity vs no signal. One forum history described 1 mg/day SubQ Vesugen for 20 days with 2 mg/day Cartalax after FGF-18; later updates added more agents and explicitly said causality was blurred. It does not establish an isolated Vesugen response. forumanecdote
- Weeks 2–8 post-course: Residual benefit framed as ‘after the course’ (gene-expression tradition), not day-to-day drug feel. forum
- Months 3–6: Decision point for 2–4× yearly re-runs rather than open-ended daily use in classic bioregulator calendars. forum
- No change: Re-check BP, lipids, sleep, walking load, meds, product identity/purity — not automatic multi-mg escalation. forum
- Week 3–4 (oral month courses): ED/limb-flow literature and oral charts often judge around end of a ~30-day capsule block. trial
- ~4-month follow-up talk: The small ED/limb series is often cited for benefits still discussed months after a one-month course — uncontrolled. trial
Cycles people discuss
- Classic short block: ~10–20 consecutive days — dominant Khavinson-style injectable and many clinic writeups. forum
- Oral month block: ~20–30 days / ~1 month of capsules or drops is the most common commercial cytogen guidance. forum
- Injectable research courses: ~10–30 days SC once daily is the usual gray-market window; some extend to 4–6 weeks. forum
- Long titration courses: 8–12+ week daily ramps appear on dosage sites; these are community innovations, not the historical short-course literature standard. forum
- Off / spacing: Courses often repeated every ~3–6 months (~2–4× yearly); some charts say repeat after 1–3 months when stacking with other vessel products. forum
- Cytogen → cytomax sequence: Common calendar: Vesugen (cytogen) ~1 month for faster onset, then Ventfort (cytomax vessel complex) ~2 months for longer-hold support — ratios and brands vary. forum
- Continuous daily year-round: Less common and framed non-standard vs classic bioregulator on/off calendars. forum
- Multi-organ rotations: Often run inside 3–5 bioregulator sets (e.g., pineal + thymus + vessel ± organ-specific) rather than lifelong solo daily Vesugen. forum
- Re-run triggers: Seasonal calendars, pre-travel/training blocks, or recheck of extremity comfort / sexual-function logs — multi-year gray-market safety databases lacking. forum
Timing
- Molecular size: ~390 Da hydrophilic tripeptide — expected short plasma residence; forums treat it as hours-scale, supporting once-daily (or multi-dose oral/sublingual) in-course dosing, not weekly depot. forum
- Why short courses anyway: Gene-expression / bioregulator practice tradition claims effects outlast blood peptide, not long plasma half-life. forum
- After-course feel: Users separate ‘peptide still in blood’ from weeks-to-months of claimed circulation steadiness — anecdote, not measured PK. anecdote
- Oral timing habits: With meals or 5–10 min before meals, 1–2× daily; empty-stomach preference appears in some longevity blogs. forum
- Injectable timing: Usually once daily (often morning); split BID mainly when chasing higher multi-mg totals. forum
- Sublingual timing: Multi-times-daily before food to allow mucosal contact time (~10–15 min hold). forum
- Mechanism implication for dose size: DNA-binding / epigenetic hypotheses historically justified microgram-to-low-mg courses; that logic sits in tension with multi-mg daily inject escalations that lack dose-response curves. forum
- PK honesty: Modern published human half-life, bioavailability, and clearance packages for synthetic Vesugen are essentially absent. trial
More on what it is
- Not Ventfort: Ventfort is the natural vessel-complex cytomax (aortic-tissue peptide mix); Vesugen is the synthetic KED sequence positioned as the faster cytogen counterpart — not the same product. forum
- Why people search it: Longevity niche wants a dedicated vascular peer to Epitalon; gray-market 20 mg vials and oral cytogen capsules both circulate. forum
- Research lens: Match species, endpoint, oral cytogen vs injectable lyophilizate identity, and short-course vs vendor ‘8–12 week ramp’ before trusting vessel claims. forum
- What it is: Synthetic tripeptide Lys-Glu-Asp (KED); ~390 Da; CAS 204271-66-9; PubChem CID 87571363; Khavinson-line vascular bioregulator often labeled T-38 / cytogen. trial
- Class framing: ‘Vessel-specific’ short peptide parallel to Epitalon (pineal) and Vilon (immune) in multi-organ bioregulator calendars. forum
- Mechanism talk: Nuclear/DNA-binding gene-expression stories (Ki-67/MKI67, SIRT1, endothelin-1, connexins, eNOS/NO) rather than classical surface-receptor agonism. lab
- Evidence honesty: Dense originating-group in-vitro/animal work + small older Russian observational series; no modern Western RCTs or published human PK dose-ranging. trial
- Not a substitute for: Statins, antiplatelets, ACE inhibitors/ARBs, PDE5 inhibitors, revascularization, or emergency CV care. trial
Stacks
- Ventfort (primary pair): Vesugen as cytogen ‘fast’ vascular phase then Ventfort cytomax for longer support — or oral Ventfort alongside injectable KED in forum posts. forum
- Cardiogen / Chelohart: Vessel peptide + heart-muscle bioregulator for ‘full CV kit’ talk. forum
- Epitalon (± Pinealon): Longevity ‘base’ — pineal/telomere narratives plus vascular cytogen. forum
- Thymalin / Vilon / Crystagen: Immune-axis peers in classic multi-organ Khavinson calendars (Khavinson-style ‘big three’ often framed pineal + thymus + circulatory). forum
- Pinealon or Semax-class: Cognition + cerebral perfusion stack logic. forum
- Testoluten (male reproductive talk): Minority ‘vasculogenic sexual health’ calendars pair vessel peptide with testicular bioregulator. forum
- Multi-organ rotations: Cartalax, Chonluten, Ovagen, etc., on rotating organ calendars rather than lifelong solo daily Vesugen. forum
- Lifestyle co-stack (credited when outcomes look good): Walking, BP control, sleep, lipid management, smoking cessation — often do more measurable work than the peptide alone. forum
- Avoid double-counting same tissue: Stacking two vessel products at full dose without a plan is common; start 1–2 bioregulators and track one endpoint. forum
- Not a PDE5 stack substitute: Some bro talk pairs vessel peptides with PDE5s for ED; that is off-label improvisation, not a studied fixed combo. anecdote
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- GI (oral): Mild stomach upset, bloating, or discomfort — uncommon and usually transient in community reports. forum
- Injection site: Redness, sting, itch, or irritation — technique and diluent dependent. forum
- Systemic noise: Headache, light fatigue, vague ‘adjustment’ feelings — causality unclear and often confounded by stacks. forum
- Allergy / hypersensitivity: Rare theoretical risk to peptide or residual synthesis impurities; stop narratives if rash, swelling, or breathing issues. forum
- Theoretical angiogenesis / proliferative concern: Because proliferation/Ki-67 and vessel-support stories are the pitch, community cautions flag active malignancy or cancer history as reason to avoid self-experimentation — hypothesis-level, not proven harm or benefit. forum
- Pregnancy / breastfeeding: No adequate safety data; standard research-only exclusion. forum
- Kidney / liver disease caution: General peptide-handling caution in moderate–severe organ disease without clinical supervision. forum
- CV med interactions unknown: Concurrent antihypertensives, anticoagulants, or antiplatelets — no formal interaction trials; do not treat as license to drop prescribed drugs. forum
- Not proven primary care: Does not replace antiplatelet therapy, statin, BP meds, glycemic control, or emergency evaluation of chest pain / limb ischemia / sudden ED change. forum
- Long-term data gap: No solid multi-year safety database for continuous or repeatedly cycled gray-market synthetic KED. forum
- Source / purity risk: Mislabel, under/over-fill, contamination, and wrong sequence are structural research-chemical risks. forum
- Dose-chart chaos risk: Confusing oral capsule mg, microgram inject charts, and 8–12 week ramps can produce unintended multi-mg daily exposure without evidence. forum
- Overall tone in sources: Short courses often described as well tolerated; serious AE signals sparse in available Russian notes — still not the same as modern safety packages. trial
- Mechanistic flags from broader short-peptide work: Mixed experimental oxidative/proliferation notes across the class — not risk-free ‘natural amino acids only’ marketing. animal
- Research-only framing: Educational discussion of community practice — not a recommendation to use in humans or animals. forum
- Regulatory: Not FDA/EMA approved for vascular disease, hypertension, ED, or anti-aging; ‘research only’ labels are routinely misused. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.